Ireland
--:--IST
Recruiting Not applicable

Microvascular Obstruction Diagnosis Using the CoFI™ System Assessment - II

NCT06909578 · tracked via the Priya Life Science USA tracker
Sponsor
CorFlow Therapeutics AG
Phase
Not applicable
Started
2025-09-01
Last updated
2026-11-20

Condition(s) studied

Microvascular Obstruction (MVO)STEMI - ST Elevation Myocardial InfarctionPPCI

Investigational drug(s) / intervention(s)

CorFlow Controlled Flow Infusion System - CoFI™

CorFlow Controlled Flow Infusion System - CoFI™: The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.

Study summary

A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations.

Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Clinical: 1. Subject ≥18 years of age 2. Ability to provide written informed consent according to GCP and governing regulations 3. Diagnosis of acute anterior STEMI 4. First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic 1\. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation. Exclusion Criteria Clinical: 1. Cardiogenic shock 2. Thrombolytic therapy administered for this STEMI 3. Contraindication to CMRI 1. Cardiac pacemaker or implantable defibrillator; 2. Non-MRI compatible aneurysm clip; 3. Neural Stimulator (i.e., TENS unit); 4. Any implanted or magnetically activated device (insulin pump); 5. Any type of non-MRI compatible ear implant; 6. Metal shavings in the orbits; 7. Any metallic foreign body, shrapnel, or bullet in a location which the physician feels would present a risk to the subject; 8. Any history indicating contraindication to MRI 9. Inability to follow breath hold instructions or to maintain a breath hold for \>15 seconds; and 10. Known hypersensitivity or contraindication to gadolinium con-trast. 4. Subject with previous Q-Wave MI and/or known cardiomyopathy (ischemic and non ischemic), ventricular pseudoaneurysm, Ventricular Septal Defect, severe mitral valve regurgitation (with or without papillary muscle rupture), severe known cardiac valvular stenosis or insufficiency, pericardial disease 5. Major bleeding ≤ 30d prior to intervention 6. Major surgery ≤ 30d prior to intervention 7. TIA or stroke ≤ 30d prior to intervention 8. Heart failure with inotrope support and/or consideration for LVAD or heart transplant 9. Presence of an intra-aortic balloon pump 10. Known severe renal disease with creatinine \> 2.5 mg/dL and/or eGFR \< 30 mL/min/1.73 m2 11. Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the CIP, confound the data interpretation, or is associated with limited life expectancy of less than one year 12. Current participation in another clinical study 13. Pregnancy PPCI \& Angiographic: 1. CABG of LAD 2. Unsuitable target vessel anatomy (excessive tortuosity, diffuse disease, or moderate/heavy calcification) 3. Cardiac condition preventing the use of the CoFI System 4. Any angiographic post stenting condition that according to the physician requires treatment targeting no-reflow/MVO 5. Cardiac condition mandating elective PCI/CABG procedure prior to CMRI

Primary outcome measure(s)

  • Primary Effectiveness Endpoint — From enrollment to the end of treatment at 6 Months
    Diagnostic performance is measured using the two co-primary endpoints, sensitivity and specificity of the CoFI system in detecting MVO in relation to the pre-set pCoFI threshold of 124 mmHg. The analysis will be per-protocol (PP) (primary) and the full analysis set (FAS) (secondary). The control is by LGE CMRI. Hypothesis Both Sensitivity and Specificity will be tested to meet the acceptance criteria: i. The lower bound of the 95% confidence interval (CI) for sensitivity is ≥ 70% ii. The lower bound of the 95% CI for specificity is ≥ 65% These co-primary endpoints are evaluated under a joint hypothesis-testing framework. Primary Safety Endpoint Composite of device- or procedure-related mortality, clinically driven target vessel/lesion revascularization, stent thrombosis and device- or procedure related vessel dissection assessed at 30 days, as adjudicated by the CEC.

Trial sites (25)

FacilityCityRegionStatus
Ronald Reagan UCLA Medical Center Los Angeles California Recruiting
ChristianaCare - Christiana Hospital Newark Delaware Recruiting
Advocate Good Samaritan Hospital Downers Grove Illinois Not Yet Recruiting
Henry Ford Hospital Detroit Michigan Not Yet Recruiting
Corewell Health William Beaumont University Hospital Royal Oak Michigan Not Yet Recruiting
Trinity Health Ann Arbor Hospital Ypsilanti Michigan Recruiting
Allina Health Mercy Hospital Coon Rapids Minnesota Recruiting
Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital Minneapolis Minnesota Recruiting
Montefiore Medical Center The Bronx New York Recruiting
Atrium Health Carolinas Medical Center Charlotte North Carolina Recruiting
The Christ Hospital Cincinnati Ohio Recruiting
OhioHealth Riverside Methodist Hospital Columbus Ohio Recruiting
WVU Medicine - J.W. Ruby Memorial Hospital Morgantown West Virginia Recruiting
Aurora St. Luke's Medical Center Milwaukee Wisconsin Recruiting
University Hospital of Ferrara - Sant'Anna Hospital Ferrara Italy Not Yet Recruiting
Humanitas Research Hospital Milan Italy Not Yet Recruiting
Monzino Cardiology Center Milan Italy Not Yet Recruiting
Umberto I University Hospital - Sapienza University of Rome Rome Italy Not Yet Recruiting
City of Health and Science University Hospital of Turin - Molinette Hospital Turin Italy Not Yet Recruiting
Integrated University Hospital of Verona - Borgo Trento Hospital Verona Italy Not Yet Recruiting
The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos Kaunas Lithuania Recruiting
Vilnius University Hospital Santariskiu Klinikos Vilnius Lithuania Recruiting
Dedinje Institute for Cardiovascular Diseases Belgrade Serbia Not Yet Recruiting
Valjevo General Hospital Valjevo Serbia Not Yet Recruiting
Cardiocentro Ticino Lugano Canton Ticino Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06909578 on ClinicalTrials.gov ↗ ← All trials in the USA